Verily Health has secured new investment from NVIDIA and existing backer CU Healthcare Innovation Fund II as the precision health technology company expands its data and artificial intelligence platform. The financing extends Verily’s March fundraising. The company did not disclose the size of the additional investments. Verily’s existing investors also include Alphabet, Series X Capital and UCHealth.
The new capital will support continued adoption of Verily Pre, the company’s flagship data and AI platform designed to help healthcare organizations prepare complex health data for AI applications and deploy the technology responsibly across research and patient care.
Verily is also expanding Verily Me, its patient-engagement offering intended to support individuals throughout their healthcare journeys.
NVIDIA and Verily already have a technology relationship dating to October 2025.
Researchers using Verily Pre can access NVIDIA technologies including NeMo, Parabricks, RAPIDS and B200 GPUs.
The companies also collaborated on Forecast 1.0, a foundation model combining genomics and electronic health record information to improve predictions of long-term health risks. Verily said use of NVIDIA’s AI stack improved both predictive performance and computational efficiency.
Verily’s broader strategy is to turn multimodal healthcare data into AI models and actionable insights that can make healthcare more personalized, predictive and precise.
The addition of NVIDIA as an investor deepens that relationship as Verily attempts to become an infrastructure layer connecting healthcare data with increasingly sophisticated AI systems.
KEY QUOTE:
“Together, these investments and the continued support of our current investors accelerate our vision to build a trusted foundation for healthcare, bringing together the information and intelligence needed to power better decisions and unlock the full potential of AI across the healthcare ecosystem.”
Stephen Gillett, Chairman and CEO of Verily
